An as yet unpublished study reporting the emergence of artemisinin-resistant malaria in Cambodia is getting a fair share of attention. The study was first alluded to by a 20 May Bloomberg story, now unavailable on the Bloomberg site but still available here.

Roll forward 8 days and to a BBC reporter on the ground in Cambodia, reporting directly from the site of two clinical trials, where the news seems to be coming from. The BBC then ran another story that says: “International scientists say they have found the first evidence of resistance to the world’s most effective drug for treating malaria. They say the trend in western Cambodia has to be urgently contained because full-blown resistance would be a global health catastrophe.”

In the UK, science reporters were then bombarded with offers of comments from expert malaria scientists, courtesy of the Science Media Centre, and the story took off. The Daily Mail has the considered “Killer new malaria bug discovered” headline for one, although other reports are somewhat more measured.

The studies are not yet complete, nor published or peer-reviewed. The WHO has no updates on its website about this work.

That doesn’t mean it isn’t important, but with stories mysteriously disappearing, and no signs of any reports, it is hard to form a firm opinion about the dangers. Of course, artemisinin should not be used on its own, but in combination with another anti-malarials, and in 2006 WHO recommendations were taken on board by 13 pharma companies to stop selling single-drug malaria medications.

The news from Cambodia doesn’t sound good, but the real extent of the situation will not be made clearer by a rash of media reports. We need to await the clinical trial data, and the peer-reviewed results of those trials.